indiana-university-school-of-medicine

Indiana University School of Medicine

Overview

Indiana University School of Medicine

Overview

Indiana University School of Medicine (IUSM) is the largest medical school in the United States, with over 1,800 medical students and more than 3,000 residents and fellows in training. Founded in 1903, the school maintains a comprehensive research portfolio spanning basic neuroscience, translational medicine, and clinical trials for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. The institution's research programs emphasize the intersection of sleep biology, neuroinflammation, and protein aggregation pathologies that characterize these conditions["@iu-som-2023"].

Location and Organization

The School of Medicine is headquartered in Indianapolis with eight regional campuses across Indiana:

• Indianapolis: Central campus and main research facilities
• Bloomington: Partnership with Indiana University Bloomington
• Fort Wayne: Northern Indiana regional campus
• South Bend: South Bend campus
• Terre Haute: Western Indiana campus
• Evansville: Southern Indiana campus
• Muncie: East Central campus
• West Lafayette: Partnership with Purdue University

Neurodegeneration Research Programs

Sleep and Circadian Biology in Neurodegeneration

Indiana University School of Medicine has established a leading research program investigating the bidirectional relationship between sleep disturbances and neurodegenerative disease. This research direction emerged from observations that sleep fragmentation and reduced slow-wave sleep are among the earliest detectable changes in both Alzheimer's disease and Parkinson's disease, often preceding clinical diagnosis by years or decades[@elder2010].

The IUSM Sleep and Brain Health research program examines how sleep-dependent glymphatic clearance mechanisms are impaired in neurodegenerative conditions. The glymphatic system, first characterized by Iliff and colleagues, represents a brain-wide waste clearance pathway that operates primarily during sleep, when interstitial space expands by more than 60%, facilitating the removal of metabolic waste products including amyloid-beta and tau proteins[@iliff2014][@xie2013].

Research conducted in collaboration with the Stark Neurosciences Research Institute has demonstrated that glymphatic function is significantly impaired in mouse models of Alzheimer's disease, particularly in limbic system structures critical for memory formation[@yuede2020]. This work has established that amyloid-beta accumulation in the brain parenchyma correlates with reduced perivascular aquaporin-4 (AQP4) polarization, compromising the convective bulk flow that drives waste clearance[@boken2021].

Clinical studies at IUSM have documented that patients with mild cognitive impairment and early-stage Alzheimer's disease show reduced cerebrospinal fluid turnover rates compared to age-matched controls, suggesting that impaired glymphatic clearance may contribute to protein aggregation even in prodromal disease stages[@zhen2022]. The Sleep and Neurodegeneration research program has proposed that enhancing glymphatic function through sleep optimization, exercise, or pharmacological interventions could slow disease progression.

Alzheimer's Disease Research

The Alzheimer's disease research program at IUSM encompasses multiple investigative directions spanning basic science, biomarker development, and clinical trials. Key research areas include:

Amyloid and Tau Biology: IUSM investigators study the molecular mechanisms underlying amyloid-beta aggregation and tau hyperphosphorylation, with emphasis on identifying therapeutic targets that might prevent or reverse these pathological processes. Current projects examine the role of sleep deprivation in accelerating amyloid plaque formation, building on seminal work demonstrating that a single night of sleep deprivation increases amyloid burden in healthy adults[@shokri-kojori2018].

Neuroinflammation: The neuroinflammation research program investigates how chronic microglial activation contributes to neurodegeneration. IUSM researchers have characterized the temporal sequence of inflammatory changes in Alzheimer's disease models, demonstrating that pro-inflammatory cytokines emerge early in disease pathogenesis and may serve as therapeutic targets or biomarkers[@wilson2023].

Vascular Contributions: Recognizing that vascular dysfunction and neurodegenerative processes interact bidirectionally, IUSM investigators study the neurovascular unit in Alzheimer's disease, examining how blood-brain barrier breakdown, reduced cerebral blood flow, and vascular risk factors contribute to disease progression[@barucker2018][@zhang2017].

Parkinson's Disease Research

The Parkinson's disease research program at IUSM focuses on understanding alpha-synuclein pathology, Lewy body formation, and mechanisms of dopaminergic neuron degeneration. The Stark Neurosciences Research Institute houses investigators studying:

Alpha-Synuclein Aggregation: Research examines the conformational changes in alpha-synuclein that lead to fibril formation and Lewy body pathology. Studies investigate how cellular quality control mechanisms (autophagy, ubiquitin-proteasome system) fail in PD, leading to protein aggregate accumulation.

Cell-Based Therapies: IUSM investigators are developing cell replacement strategies for Parkinson's disease, including dopaminergic neuron transplantation and induced pluripotent stem cell (iPSC) approaches. Research addresses challenges related to cell survival, integration, and immune compatibility following transplantation[@kolb2019].

Sleep Disorders in PD: Recognizing that sleep disturbances are among the most common non-motor symptoms of Parkinson's disease, with up to 90% of PD patients experiencing insomnia, REM sleep behavior disorder, or excessive daytime sleepiness, IUSM researchers investigate how these symptoms relate to underlying disease pathology and whether they may serve as biomarkers or therapeutic targets[@bacik2022].

Key Research Centers and Facilities

Stark Neurosciences Research Institute

The Stark Neurosciences Research Institute serves as the hub for neuroscience research at IUSM, bringing together over 100 faculty investigators across departments of Neurology, Neuroscience, Psychiatry, Radiology, and Biomedical Engineering. The Institute provides:

• Core Facilities: Confocal microscopy, behavioral testing, viral vector production, histology
• Clinical Research Unit: Phase I-III clinical trials infrastructure
• Preclinical Models: Transgenic mouse models, iPSC lines, viral vector models
• Neuroimaging: PET/CT, MRI, dedicated research scanner

Indiana Alzheimer's Disease Research Center

The Indiana Alzheimer's Disease Research Center (IADRC), funded by the National Institute on Aging, conducts comprehensive research on the biology, diagnosis, and treatment of Alzheimer's disease and related disorders. The Center:

• Maintains a longitudinal cohort of over 500 participants with annual cognitive testing, MRI, PET imaging, and CSF biomarker collection
• Provides tissue bank access through the IUSM brain bank program
• Supports pilot grants for early-career investigators
• Offers neuroimaging and bioinformatics cores

Center for Parkinson's Disease and Movement Disorders

This specialized center provides comprehensive care while conducting clinical trials and observational studies in Parkinson's disease and related movement disorders. The Center:

• Offers deep brain stimulation programming andbotulinum toxin injection services
• Conducts clinical trials for new PD therapeutics
• Maintains a PD registry with longitudinal follow-up
• Supports translational research through the PD Biobank

Notable Faculty and Their Contributions

IUSM faculty have made significant contributions to understanding neurodegenerative disease mechanisms and developing new therapeutic approaches:

Sleep and Neurodegeneration Research

Indiana University has been particularly influential in establishing the link between sleep disturbances and Alzheimer's disease pathogenesis. The research program has demonstrated that orexin (hypocretin) neurons, which regulate arousal and wakefulness, also modulate amyloid-beta production[@kang2023]. This work suggests that optimizing sleep architecture or targeting orexin signaling might reduce amyloid accumulation in at-risk individuals.

The clinical research program has documented that REM sleep behavior disorder (RBD) precedes the motor symptoms of Parkinson's disease by years or decades in many patients, suggesting that RBD may represent an early prodromal phase of synucleinopathy[@postuma2019]. This observation has important implications for early intervention strategies.

Tau Research

IUSM investigators study tau propagation and seeding mechanisms in Alzheimer's disease and primary tauopathies. Research has characterized how pathological tau spreads through connected neural circuits, with implications for understanding disease progression and developing interventions targeting tau pathology[@friedman2018].

Clinical Trials and Therapeutics Development

IUSM conducts numerous clinical trials for neurodegenerative diseases through the Indiana Clinical and Translational Sciences Institute (CTSI) and the research centers described above:

Active Trial Areas

• Disease-Modifying Therapies: Anti-amyloid antibodies, anti-tau compounds, alpha-synuclein modulators
• Symptomatic Treatments: Cognitive enhancers, motor symptoms medications
• Non-Pharmacological Interventions: Exercise, cognitive training, sleep optimization
• Biomarker Studies: PET imaging, CSF biomarkers, digital health measures

Clinical Trial Infrastructure

The school maintains a Clinical Trials Office that provides:

• Protocol development and regulatory support
• Participant recruitment and screening
• Data management and statistical analysis
• Clinical monitoring and quality assurance

Education and Training Programs

IUSM offers extensive training in neurodegenerative disease research through multiple programs:

Medical Student Education

• Neuroscience Course: Second-year medical students receive comprehensive training in neurobiology, including neurodegenerative disease mechanisms
• Clinical Clerkships: Third-year students rotate through neurology, with exposure to AD, PD, and other neurodegenerative conditions
• Research Track: Students can pursue a research year with neurodegeneration faculty

Residency and Fellowship

• Neurology Residency: Four-year program with dedicated neurodegeneration rotations
• Movement Disorders Fellowship: ACGME-accredited fellowship in Parkinson's disease and related disorders
• Memory Disorders Fellowship: Training in Alzheimer's disease and other dementias
• Sleep Medicine Fellowship: Cross-disciplinary training in sleep disorders relevant to neurodegeneration

Graduate and Postdoctoral Training

• Neuroscience Graduate Program: PhD training in molecular, cellular, and systems neuroscience
• Postdoctoral Fellowships: NIH-funded training positions in neurodegeneration research
• Clinical Research Training: Master's and certificate programs in clinical investigation

Regional Medical Education Network

IUSM's distributed campus model serves Indiana's healthcare needs while providing unique research opportunities. The regional campuses train medical students who return to practice in underserved areas of the state, creating a network of clinicians familiar with neurodegenerative disease management in rural and suburban communities[@tynes2013].

The regional campuses also participate in clinical trials, expanding access for Indiana residents to cutting-edge therapies while generating diverse patient cohorts for research studies.

Collaboration and Partnerships

IUSM maintains active collaborations with:

• National Institutes of Health: NIA, NINDS, NHLBI funded research projects
• Alzheimer's Association: Part of the Alzheimer's Disease Research Centers network
• Michael J. Fox Foundation: Parkinson's disease research collaborations
• Indiana University Health: Clinical care partnerships
• Purdue University: Cross-institutional research collaborations in engineering and pharmacy

Future Directions

The neurodegeneration research program at IUSM is expanding in several key directions:

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Sleep and Neurodegeneration](/mechanisms/sleep-neurodegeneration-link)
• [Glymphatic System](/mechanisms/glymphatic-system)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Tau Protein](/proteins/tau)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Indiana University](/institutions/indiana-university)

External Links

• [Indiana University School of Medicine](https://medicine.iu.edu)
• [Stark Neurosciences Research Institute](https://neurosciences.iu.edu)
• [Indiana Alzheimer's Disease Research Center](https://iadrc.iu.edu)
• [Parkinson's Disease Center](https://movementdisorders.iu.edu)
• [Clinical Trials Office](https://clinicaltrials.iu.edu)

References